Basecamp Research Raises $140M Series C to Advance AI Therapeutics

### Money Play Capital deployment toward artificial intelligence platforms and life sciences continues to influence venture-backed biotech ecosystems, though no direct public equity vehicles are named in the primary transaction.

## Catalyst Analysis: Series C Financing & EDEN Platform Scale Basecamp Research announced an oversubscribed $140M Series C financing round on Wednesday, September 23, 2026, led by S32 with participation from NVIDIA, Menlo Ventures' Anthology Fund, and other institutional backers. The company applies its EDEN biological foundation model to in vivo cell therapy, aiming to reprogram cells inside the human body. Leadership highlighted that the funding will advance a pipeline of AI-designed medicines toward clinical development while expanding pharmaceutical partnerships globally.

## Technical Analysis & Key Risk Watch

Key levels for $NVDA+WL (educational): R2 $229.26 · R1 $227.49 · last $227.38 · S1 $224.86 · S2 $223.71.

Market participants tracking broader AI and life sciences infrastructure note that sector-wide capital allocation relies heavily on sustained venture funding rounds and validation of preclinical models. Execution risks remain tied to clinical trial timelines and the scaling costs associated with writing DNA sequences into cells.

## Impact on Venture and Biotechnology Sectors Participation from prominent institutional investors and industry leaders—such as André Hoffmann, Vice-Chairman of Roche—underscores the ongoing convergence of artificial intelligence and personalized medicine. The round positions Basecamp Research to scale its operations in London and Cambridge, Massachusetts, as venture deployment targets computational biology platforms.